NAGE News

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen ®

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen ®, the Leading NAD+ Supplement in the U.S.*

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Niagen Bioscience Announces $10 Million Share Repurchase Program